About Cyclin-L1
Cyclin-L1 (CCNL1) is a protein
from Homo sapiens identified by UniProt accession
Q9UK58, 526 residues long.
MolForge cross-references it against 0 known binders and
104 disease associations.
Target properties
| Protein name | Cyclin-L1 |
| UniProt accession | Q9UK58 |
| Gene | CCNL1 |
| Organism | Homo sapiens |
| Length | 526 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (104)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- body height · score 0.29
- body mass index · score 0.29
- electrocardiography · score 0.27
- triglyceride measurement · score 0.23
- testosterone measurement · score 0.23
- PR interval · score 0.21
- coronary artery disease · score 0.19
- neurofibrillary tangles measurement · score 0.19
- BMI-adjusted waist-hip ratio · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UK58-F1 | alphafold | PREDICTED | 68.41 | — |
Amino-acid sequence (526 residues)
MASGPHSTAT AAAAASSAAP SAGGSSSGTT TTTTTTTGGI LIGDRLYSEV SLTIDHSLIP EERLSPTPSM QDGLDLPSET DLRILGCELI QAAGILLRLP QVAMATGQVL FHRFFYSKSF VKHSFEIVAM ACINLASKIE EAPRRIRDVI NVFHHLRQLR GKRTPSPLIL DQNYINTKNQ VIKAERRVLK ELGFCVHVKH PHKIIVMYLQ VLECERNQTL VQTAWNYMND SLRTNVFVRF QPETIACACI YLAARALQIP LPTRPHWFLL FGTTEEEIQE ICIETLRLYT RKKPNYELLE KEVEKRKVAL QEAKLKAKGL NPDGTPALST LGGFSPASKP SSPREVKAEE KSPISINVKT VKKEPEDRQQ ASKSPYNGVR KDSKRSRNSR SASRSRSRTR SRSRSHTPRR HYNNRRSRSG TYSSRSRSRS RSHSESPRRH HNHGSPHLKA KHTRDDLKSS NRHGHKRKKS RSRSQSKSRD HSDAAKKHRH ERGHHRDRRE RSRSFERSHK SKHHGGSRSG HGRHRR
Explore Cyclin-L1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets